[go: up one dir, main page]

HRP20100113T1 - Upotreba pripravaka koji sadrže antagonist kapa-opioidnog receptora, namijenjenih liječenju disocijativnih poremećaja - Google Patents

Upotreba pripravaka koji sadrže antagonist kapa-opioidnog receptora, namijenjenih liječenju disocijativnih poremećaja Download PDF

Info

Publication number
HRP20100113T1
HRP20100113T1 HR20100113T HRP20100113T HRP20100113T1 HR P20100113 T1 HRP20100113 T1 HR P20100113T1 HR 20100113 T HR20100113 T HR 20100113T HR P20100113 T HRP20100113 T HR P20100113T HR P20100113 T1 HRP20100113 T1 HR P20100113T1
Authority
HR
Croatia
Prior art keywords
opioid receptor
receptor antagonist
treatment
cap
preparations containing
Prior art date
Application number
HR20100113T
Other languages
English (en)
Croatian (hr)
Inventor
Lars Hermann Holger
Original Assignee
Emodys Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102006015733A external-priority patent/DE102006015733A1/de
Priority claimed from DE102006016991A external-priority patent/DE102006016991A1/de
Application filed by Emodys Gmbh filed Critical Emodys Gmbh
Publication of HRP20100113T1 publication Critical patent/HRP20100113T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HR20100113T 2006-04-04 2007-04-03 Upotreba pripravaka koji sadrže antagonist kapa-opioidnog receptora, namijenjenih liječenju disocijativnih poremećaja HRP20100113T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006015733A DE102006015733A1 (de) 2006-04-04 2006-04-04 Verwendung von Buprenorphin und Buprenorphin-Derivaten zur Herstellung eines Medikaments zur Behandlung von emotional instabiler Persönlichkeitsstörung, Alkoholabhängigkeit und/oder multipler Substanzabhängigkeit
DE102006016991A DE102006016991A1 (de) 2006-04-11 2006-04-11 Verwendung von kappa-Opioidrezeptor-Antagonisten zur Behandlung von dissoziativen Störungen
PCT/EP2007/053248 WO2007115975A2 (de) 2006-04-04 2007-04-03 Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen

Publications (1)

Publication Number Publication Date
HRP20100113T1 true HRP20100113T1 (hr) 2010-04-30

Family

ID=38110094

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100113T HRP20100113T1 (hr) 2006-04-04 2007-04-03 Upotreba pripravaka koji sadrže antagonist kapa-opioidnog receptora, namijenjenih liječenju disocijativnih poremećaja

Country Status (17)

Country Link
US (1) US8063059B2 (ru)
EP (1) EP2001456B1 (ru)
JP (1) JP5128578B2 (ru)
AT (1) ATE450256T1 (ru)
AU (1) AU2007236003B2 (ru)
CA (1) CA2646899C (ru)
CY (1) CY1109862T1 (ru)
DE (1) DE502007002185D1 (ru)
DK (1) DK2001456T3 (ru)
EA (1) EA014820B1 (ru)
ES (1) ES2337622T3 (ru)
HR (1) HRP20100113T1 (ru)
PL (1) PL2001456T3 (ru)
PT (1) PT2001456E (ru)
RS (1) RS51211B (ru)
SI (1) SI2001456T1 (ru)
WO (1) WO2007115975A2 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009206653B2 (en) 2008-01-22 2013-07-18 Eli Lilly And Company Kappa selective opioid receptor antagonist
SG11201604944PA (en) * 2013-12-20 2016-07-28 Lundbeck & Co As H Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
WO2015095644A1 (en) 2013-12-20 2015-06-25 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
SMT201800073T1 (it) 2014-04-28 2018-03-08 Orphomed Inc Dimero di buprenorfina e suo uso nel trattamento di disturbi gastrointestinali
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
EP4489730A1 (en) 2022-03-07 2025-01-15 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028612A (en) 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
AU2981099A (en) * 1998-03-09 1999-09-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
US20020045572A1 (en) 2000-08-15 2002-04-18 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
WO2002013759A2 (en) 2000-08-15 2002-02-21 Cpd Llc Method of treating the syndrome of type 2 diabetes in humans
JP2004518654A (ja) * 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
CA2521396A1 (en) * 2003-04-04 2004-10-21 Merck & Co., Inc. Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
EP1725222A2 (en) * 2004-03-02 2006-11-29 Pharmacia Corporation Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
ES2343421T3 (es) * 2004-05-26 2010-07-30 Inotek Pharmaceuticals Corporation Derivados de purina como agonistas de los receptores a1 de adenosina y metodos de uso de los mismos.
WO2005117838A1 (en) * 2004-06-02 2005-12-15 Galephar M/F Stable oral pharmaceutical compositions of buprenorphine and derivatives

Also Published As

Publication number Publication date
CA2646899C (en) 2014-05-06
AU2007236003B2 (en) 2012-10-18
DE502007002185D1 (de) 2010-01-14
US8063059B2 (en) 2011-11-22
WO2007115975A2 (de) 2007-10-18
ES2337622T3 (es) 2010-04-27
EA200802104A1 (ru) 2009-04-28
SI2001456T1 (sl) 2010-04-30
US20090181999A1 (en) 2009-07-16
DK2001456T3 (da) 2010-04-12
WO2007115975A3 (de) 2008-02-14
JP5128578B2 (ja) 2013-01-23
AU2007236003A1 (en) 2007-10-18
ATE450256T1 (de) 2009-12-15
JP2009532434A (ja) 2009-09-10
PL2001456T3 (pl) 2010-05-31
EA014820B1 (ru) 2011-02-28
CY1109862T1 (el) 2014-09-10
EP2001456B1 (de) 2009-12-02
PT2001456E (pt) 2010-03-03
CA2646899A1 (en) 2007-10-18
EP2001456A2 (de) 2008-12-17
RS51211B (sr) 2010-12-31

Similar Documents

Publication Publication Date Title
HRP20100113T1 (hr) Upotreba pripravaka koji sadrže antagonist kapa-opioidnog receptora, namijenjenih liječenju disocijativnih poremećaja
MX346879B (es) Formulaciones de ketorolaco listas para su uso.
CA2757418C (en) Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
UA94052C2 (ru) Производные пиридазина
WO2009066152A3 (en) Haloallylamine inhibitors of ssao/vap-1 and uses therefor
RS53995B1 (en) NEW ABUSE-RESISTANT PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF OPIOID SUBSTANCE
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2006077025A3 (en) Morpholines as 5ht2c agonists
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
TW200745111A (en) New compounds
EA200970296A1 (ru) Содержащие диариловый эфир соединения мочевины
RS53266B (en) PHARMACEUTICAL FORMULATION
FR2903107B1 (fr) Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
JP2014218522A5 (ru)
TW200740764A (en) Pyrazolone derivatives
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
ECSP067111A (es) Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica
EA200900707A1 (ru) Новый способ синтеза 7,8-диметокси-1,3-дигидро-2h-3-бензазепин-2-она, и его применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
RS53521B1 (en) PREPARATION AND THERAPY APPLICATIONS (2S, 3R) -N-2 - ((3-pyridinyl) methyl) -1-AZABICYCLO [2.2.2] OCT-3-IL) -3,5-DIFLUOROBENZAMIDE
MX2011007779A (es) Formulaciones galenicas de compuestos organicos.
PH12012501965A1 (en) Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbesartan
MY148393A (en) Malate salts, and polymorphs of (3s, 5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
TR201001417A1 (tr) Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu
TNSN08506A1 (en) Substituted carboxamides